Overview
Beta-plus (β+) thalassemia is a genetic disorder characterized by reduced or absent synthesis of one beta-globin chain, leading to an imbalance in hemoglobin production and chronic hemolysis. This condition primarily affects individuals of Mediterranean, Southeast Asian, and African descent, with significant morbidity and mortality due to complications such as iron overload, bone deformities, and pulmonary hypertension. Early recognition and management are crucial as these patients often require lifelong medical intervention to prevent severe complications. Understanding the nuances of β+ thalassemia management is essential for optimizing patient outcomes in day-to-day clinical practice 1.Pathophysiology
The pathophysiology of β+ thalassemia involves multiple interconnected mechanisms that contribute to its clinical manifestations. At the molecular level, the deficiency in beta-globin chains leads to the formation of unstable tetramers like gamma-gamma or beta-delta, which are less efficient and more prone to degradation. This imbalance triggers increased red blood cell destruction (hemolysis), releasing free heme and iron into the bloodstream. Chronic hemolysis drives iron overload, which can affect multiple organs including the heart, liver, and endocrine systems. Reduced nitric oxide bioavailability exacerbates endothelial dysfunction, contributing to the development of pulmonary hypertension. Additionally, hypercoagulability, often associated with iron overload, further complicates the clinical picture by increasing the risk of thrombotic events. These multifaceted pathophysiological processes underscore the need for comprehensive, multi-targeted therapeutic approaches 1.Epidemiology
β+ thalassemia exhibits significant geographic and ethnic variability in prevalence. It is particularly common in regions with historical endemicity, such as the Mediterranean, Southeast Asia, and parts of Africa. Incidence rates vary widely, with carrier frequencies ranging from 1% to over 40% in certain populations. Age of onset and severity can differ, with some patients presenting in childhood due to significant anemia, while others may have milder forms that become clinically apparent later in life. Over time, there has been a trend towards earlier diagnosis and intervention due to improved screening methods and increased awareness, leading to better management outcomes. However, precise global incidence and prevalence figures remain challenging to consolidate due to regional disparities in reporting and healthcare infrastructure 1.Clinical Presentation
Patients with β+ thalassemia typically present with symptoms related to chronic anemia, including pallor, fatigue, and exercise intolerance. Hemolytic crises may manifest acutely with severe anemia, jaundice, and dark urine. Long-standing iron overload can lead to organ dysfunction, such as hepatomegaly, splenomegaly, and cardiac complications including arrhythmias and heart failure. Pulmonary hypertension, though less commonly recognized, can present with dyspnea, exercise intolerance, and signs of right heart strain on examination. Red-flag features include unexplained syncope, progressive dyspnea, and signs of acute chest pain, which warrant urgent evaluation for complications like pulmonary hypertension or acute thrombosis 1.Diagnosis
The diagnostic approach for β+ thalassemia involves a combination of clinical assessment, laboratory tests, and imaging studies. Initial suspicion often arises from clinical symptoms and family history. Key diagnostic criteria include:Management
First-Line Management
Second-Line Management
Refractory / Specialist Escalation
Contraindications
Complications
Prognosis & Follow-Up
The prognosis for patients with β+ thalassemia varies widely based on the severity of disease and adherence to management protocols. Key prognostic indicators include iron overload levels, presence of pulmonary hypertension, and cardiac function. Recommended follow-up intervals typically include:Special Populations
Pregnancy
Management during pregnancy requires careful monitoring of anemia, iron overload, and fetal well-being. Increased transfusion support and close obstetric surveillance are essential 1.Pediatrics
Early diagnosis and intervention are critical. Regular transfusions and chelation therapy start early to prevent organ damage. Growth and development monitoring are integral parts of follow-up care 1.Elderly
Elderly patients often have accumulated complications from long-standing disease. Focus shifts towards managing comorbidities and maintaining quality of life with tailored transfusion and chelation strategies 1.Key Recommendations
References
1 Anthi A, Orfanos SE, Armaganidis A. Pulmonary hypertension in β thalassaemia. The Lancet. Respiratory medicine 2013. link70078-X)